Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 could be developed as a novel vaccine for myeloma immunotherapy.

Original languageEnglish (US)
Pages (from-to)756-758
Number of pages3
Issue number5
StatePublished - 2012


  • DNA
  • Dickkopf-1
  • Immunotherapy
  • Multiple myeloma
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'DKK1 as a novel target for myeloma immunotherapy'. Together they form a unique fingerprint.

Cite this